Browse series

Experimental condition

Monocyte derived macrophages repsonse to LPS (129)

• 12698-135D7 (Monocyte-derived macrophages response to LPS)
• 12699-135D8 (Monocyte-derived macrophages response to LPS, 00hr15min, donor1 (t2 Subject1))
• 12700-135D9 (Monocyte-derived macrophages response to LPS, 00hr30min, donor1 (t3 Subject1))
• 12701-135E1 (Monocyte-derived macrophages response to LPS, 00hr45min, donor1 (t4 Subject1))
• 12702-135E2 (Monocyte-derived macrophages response to LPS, 01hr00min, donor1 (t5 Subject1))
• 12703-135E3 (Monocyte-derived macrophages response to LPS, 01hr20min, donor1 (t6 Subject1))
• 12704-135E4 (Monocyte-derived macrophages response to LPS, 01hr40min, donor1 (t7 Subject1))
• 12705-135E5 (Monocyte-derived macrophages response to LPS, 02hr00min, donor1 (t8 Subject1))
• 12706-135E6 (Monocyte-derived macrophages response to LPS)
• 12707-135E7 (Monocyte-derived macrophages response to LPS)

... further results

Lymphatic Endothelial cells response to Vascular endothelial growth factor C (48)

• 12260-130A1 (Lymphatic Endothelial cells response to VEGFC)
• 12261-130A2 (Lymphatic Endothelial cells response to VEGFC)
• 12262-130A3 (Lymphatic Endothelial cells response to VEGFC)
• 12263-130A4 (Lymphatic Endothelial cells response to VEGFC)
• 12264-130A5 (Lymphatic Endothelial cells response to VEGFC)
• 12265-130A6 (Lymphatic Endothelial cells response to VEGFC)
• 12266-130A7 (Lymphatic Endothelial cells response to VEGFC)
• 12267-130A8 (Lymphatic Endothelial cells response to VEGFC)
• 12268-130A9 (Lymphatic Endothelial cells response to VEGFC)
• 12269-130B1 (Lymphatic Endothelial cells response to VEGFC)

... further results

Aortic smooth muscle cell response* (60)

• 12642-134G5 (Aortic smooth muscle cell response to FGF2)
• 12643-134G6 (Aortic smooth muscle cell response to FGF2)
• 12644-134G7 (Aortic smooth muscle cell response to FGF2)
• 12645-134G8 (Aortic smooth muscle cell response to FGF2)
• 12646-134G9 (Aortic smooth muscle cell response to FGF2)
• 12647-134H1 (Aortic smooth muscle cell response to FGF2)
• 12648-134H2 (Aortic smooth muscle cell response to FGF2)
• 12649-134H3 (Aortic smooth muscle cell response to FGF2, 04hr, biol_rep1 (LK22))
• 12650-134H4 (Aortic smooth muscle cell response to FGF2)
• 12651-134H5 (Aortic smooth muscle cell response to FGF2)

... further results

natural helper cells, stimulation with IL2* (12)

• 12247-129H6 (natural helper cells, IL2 treated, day15, biol_rep1)
• 12248-129H7 (natural helper cells, IL2 treated, day15, biol_rep2)
• 12249-129H8 (natural helper cells, IL2 treated, day15, biol_rep3)
• 12250-129H9 (unclassfied)
• 12251-129I1 (unclassfied)
• 12252-129I2 (natural helper cells, IL33 treated, day02, biol_rep3)
• 12253-129I3 (natural helper cells, IL33 treated, 01hr, biol_rep1)
• 12254-129I4 (unclassfied)
• 12255-129I5 (unclassfied)
• 12256-129I6 (unclassfied)

... further results

K562 erythroblastic leukemia response to hemin (54)

• 13079-140B1 (K562 erythroblastic leukemia response to hemin, 00hr00min, biol_rep1)
• 13080-140B2 (K562 erythroblastic leukemia response to hemin, 00hr15min, biol_rep1)
• 13081-140B3 (K562 erythroblastic leukemia response to hemin, 00hr30min, biol_rep1)
• 13082-140B4 (K562 erythroblastic leukemia response to hemin, 00hr45min, biol_rep1)
• 13083-140B5 (K562 erythroblastic leukemia response to hemin, 01hr00min, biol_rep1)
• 13084-140B6 (K562 erythroblastic leukemia response to hemin, 01hr20min, biol_rep1)
• 13085-140B7 (K562 erythroblastic leukemia response to hemin, 01hr40min, biol_rep1)
• 13086-140B8 (K562 erythroblastic leukemia response to hemin, 02hr00min, biol_rep1)
• 13087-140B9 (K562 erythroblastic leukemia response to hemin, 02hr30min, biol_rep1)
• 13088-140C1 (K562 erythroblastic leukemia response to hemin, 03hr00min, biol_rep1)

... further results

MCF7 breast cancer cell line response to Epidermal Growth Factor 1 (48)

• 13031-139E7 (MCF7 breast cancer cell line response to EGF1, 00hr00min, biol_rep1)
• 13032-139E8 (MCF7 breast cancer cell line response to EGF1)
• 13033-139E9 (MCF7 breast cancer cell line response to EGF1)
• 13034-139F1 (MCF7 breast cancer cell line response to EGF1)
• 13035-139F2 (MCF7 breast cancer cell line response to EGF1)
• 13036-139F3 (MCF7 breast cancer cell line response to EGF1)
• 13037-139F4 (MCF7 breast cancer cell line response to EGF1)
• 13038-139F5 (MCF7 breast cancer cell line response to EGF1)
• 13039-139F6 (MCF7 breast cancer cell line response to EGF1)
• 13040-139F7 (MCF7 breast cancer cell line response to EGF1)

... further results

MCF7 breast cancer cell line response to Heregulin (45)

• 13048-139G6 (MCF7 breast cancer cell line response to HRG)
• 13049-139G7 (MCF7 breast cancer cell line response to HRG)
• 13050-139G8 (MCF7 breast cancer cell line response to HRG)
• 13051-139G9 (MCF7 breast cancer cell line response to HRG)
• 13052-139H1 (MCF7 breast cancer cell line response to HRG)
• 13053-139H2 (MCF7 breast cancer cell line response to HRG)
• 13054-139H3 (MCF7 breast cancer cell line response to HRG)
• 13055-139H4 (MCF7 breast cancer cell line response to HRG)
• 13056-139H5 (MCF7 breast cancer cell line response to HRG)
• 13057-139H6 (MCF7 breast cancer cell line response to HRG)

... further results

J2E erythroblastic leukemia response to erythropoietin (48)

• 13063-139I3 (J2E erythroblastic leukemia response to erythropoietin)
• 13064-139I4 (J2E erythroblastic leukemia response to erythropoietin)
• 13065-139I5 (J2E erythroblastic leukemia response to erythropoietin)
• 13066-139I6 (J2E erythroblastic leukemia response to erythropoietin)
• 13067-139I7 (J2E erythroblastic leukemia response to erythropoietin)
• 13068-139I8 (J2E erythroblastic leukemia response to erythropoietin)
• 13069-139I9 (J2E erythroblastic leukemia response to erythropoietin)
• 13070-140A1 (J2E erythroblastic leukemia response to erythropoietin)
• 13071-140A2 (J2E erythroblastic leukemia response to erythropoietin)
• 13072-140A3 (J2E erythroblastic leukemia response to erythropoietin)

... further results

Saos-2 osteosarcoma* (108)

• 12662-134I7 (Saos-2 osteosarcoma treated with ascorbic acid and BGP to induce calcification)
• 12663-134I8 (Saos-2 osteosarcoma treated with ascorbic acid and BGP to induce calcification)
• 12664-134I9 (Saos-2 osteosarcoma treated with ascorbic acid and BGP to induce calcification)
• 12665-135A1 (Saos-2 osteosarcoma treated with ascorbic acid and BGP to induce calcification)
• 12666-135A2 (Saos-2 osteosarcoma treated with ascorbic acid and BGP to induce calcification)
• 12667-135A3 (Saos-2 osteosarcoma treated with ascorbic acid and BGP to induce calcification)
• 12668-135A4 (Saos-2 osteosarcoma treated with ascorbic acid and BGP to induce calcification)
• 12669-135A5 (Saos-2 osteosarcoma treated with ascorbic acid and BGP to induce calcification)
• 12670-135A6 (Saos-2 osteosarcoma treated with ascorbic acid and BGP to induce calcification)
• 12671-135A7 (Saos-2 osteosarcoma treated with ascorbic acid and BGP to induce calcification)

... further results

Human ES cell differentiation to melanocyte (48)

• 12626-134E7 (H9 Embryonic Stem cells, biol_rep1 (H9ES-1))
• 12627-134E8 (H9 Embryoid body cells, melanocytic induction)
• 12628-134E9 (H9 Embryoid body cells, melanocytic induction)
• 12629-134F1 (H9 Embryoid body cells, melanocytic induction)
• 12630-134F2 (H9 Embryoid body cells, melanocytic induction)
• 12631-134F3 (H9 Embryoid body cells, melanocytic induction)
• 12632-134F4 (H9 Embryoid body cells, melanocytic induction)
• 12633-134F5 (H9 Embryoid body cells, melanocytic induction)
• 12634-134F6 (H9 Embryoid body cells, melanocytic induction)
• 12635-134F7 (H9 Embryoid body cells, melanocytic induction)

... further results

ST2 mesenchymal stem cell differentiation* (90)

• 12308-130F4 (ST2 (Mesenchymal stem cells) cells, differentiation to adipocytes)
• 12309-130F5 (ST2 (Mesenchymal stem cells) cells, differentiation to adipocytes)
• 12310-130F6 (ST2 (Mesenchymal stem cells) cells, differentiation to adipocytes)
• 12311-130F7 (ST2 (Mesenchymal stem cells) cells, differentiation to adipocytes)
• 12312-130F8 (ST2 (Mesenchymal stem cells) cells, differentiation to adipocytes)
• 12313-130F9 (ST2 (Mesenchymal stem cells) cells, differentiation to adipocytes)
• 12314-130G1 (ST2 (Mesenchymal stem cells) cells, differentiation to adipocytes)
• 12315-130G2 (ST2 (Mesenchymal stem cells) cells, differentiation to adipocytes)
• 12316-130G3 (ST2 (Mesenchymal stem cells) cells, differentiation to adipocytes)
• 12317-130G4 (ST2 (Mesenchymal stem cells) cells, differentiation to adipocytes, 36hr, biol_rep1 (036hA1))

... further results

T cell differentiation (48)

• 12971-138H1 (TSt-4/DLL1 feeder cells, biol_rep1)
• 12972-138H2 (EBF KO HPCs induced to T cell)
• 12973-138H3 (EBF KO HPCs induced to T cell)
• 12974-138H4 (EBF KO HPCs induced to T cell)
• 12975-138H5 (EBF KO HPCs induced to T cell)
• 12976-138H6 (EBF KO HPCs induced to T cell)
• 12977-138H7 (EBF KO HPCs induced to T cell)
• 12978-138H8 (EBF KO HPCs induced to T cell)
• 12979-138H9 (EBF KO HPCs induced to T cell)
• 12980-138I1 (EBF KO HPCs induced to T cell)

... further results

Adipocyte differentiation (12)

• 13019-139D4 (Adipocyte differentiation)
• 13020-139D5 (Adipocyte differentiation)
• 13021-139D6 (Adipocyte differentiation)
• 13022-139D7 (Adipocyte differentiation)
• 13023-139D8 (Adipocyte differentiation)
• 13024-139D9 (Adipocyte differentiation)
• 13025-139E1 (Adipocyte differentiation)
• 13026-139E2 (Adipocyte differentiation)
• 13027-139E3 (Adipocyte differentiation)
• 13028-139E4 (Adipocyte differentiation)

... further results

epithelial sheet was isolated by manipulation with a fine needle under stereomicroscopic monitoring (12)

• 10252-104B9 (Ileum epithelium, pool1)
• 10253-104C1 (Ileum epithelium, pool2)
• 10254-104C2
• 10255-104C3
• 10256-104C4
• 10257-104C5
• 10258-104C6
• 10259-104C7
• 10260-104C8 (Ileum epithelium, treated with RANKL, day03, pool3)
• 10261-104C9

... further results

cells were sorted by MoFlo (9)

• 11845-124H9 (GP2+ M cell, pool1)
• 11846-124I1 (GP2+ M cell, pool2)
• 11847-124I2 (GP2+ M cell, pool3)
• 11848-124I3 (CD326+ enterocyte, pool1)
• 11849-124I4 (CD326+ enterocyte, pool2)
• 11850-124I5 (CD326+ enterocyte isolated from mice, treated with RANKL, day03, pool1)
• 11851-124I6 (CD326+ enterocyte isolated from mice, treated with RANKL, day03, pool2)
• 11852-124I7 (CD326++ enterocyte isolated from mice, treated with RANKL, day03, pool1)
• 11853-124I8 (CD326++ enterocyte isolated from mice, treated with RANKL, day03, pool2)

whole cell RNA (14)

• 14297-155B4
• 14300-155B7
• 14303-155C1
• 14306-155C4
• 14309-155C7
• 14312-155D1
• 14315-155D4
• 14318-155D7
• 14321-155E1
• 14324-155E4

... further results

cytoplasmic RNA (8)

• 14304-155C2
• 14307-155C5
• 14313-155D2 (Smooth Muscle Cells - Aortic, donor0 (cytoplasmic fraction))
• 14325-155E5
• 14328-155E8
• 14331-155F2 (Fibroblast - Aortic Adventitial donor2 (cytoplasmic fraction))
• 14334-155F5 (Small Airway Epithelial Cells donor2 (cytoplasmic fraction))
• 14337-155F8

nuclear RNA (14)

• 14299-155B6
• 14302-155B9 (Fibroblast - skin normal, donor2 (nuclear fraction))
• 14305-155C3 (Fibroblast - skin spinal muscular atrophy, donor3 (nuclear fraction))
• 14308-155C6 (Fibroblast - skin dystrophia myotonica, donor3 (nuclear fraction))
• 14311-155C9 (Fibroblast - Aortic Adventitial, donor3 (nuclear fraction))
• 14314-155D3 (Smooth Muscle Cells - Aortic, donor0 (nuclear fraction))
• 14317-155D6 (Small Airway Epithelial Cells, donor3 (nuclear fraction))
• 14320-155D9 (Preadipocyte - breast, donor2 (nuclear fraction))
• 14323-155E3 (Fibroblast - skin normal, donor1 (nuclear fraction))
• 14326-155E6 (Fibroblast - skin spinal muscular atrophy, donor1 (nuclear fraction))

... further results

Cellular fractionation (Nucleus / cytosol)

cells were sorted by MoFlo (9)

• 11845-124H9 (GP2+ M cell, pool1)
• 11846-124I1 (GP2+ M cell, pool2)
• 11847-124I2 (GP2+ M cell, pool3)
• 11848-124I3 (CD326+ enterocyte, pool1)
• 11849-124I4 (CD326+ enterocyte, pool2)
• 11850-124I5 (CD326+ enterocyte isolated from mice, treated with RANKL, day03, pool1)
• 11851-124I6 (CD326+ enterocyte isolated from mice, treated with RANKL, day03, pool2)
• 11852-124I7 (CD326++ enterocyte isolated from mice, treated with RANKL, day03, pool1)
• 11853-124I8 (CD326++ enterocyte isolated from mice, treated with RANKL, day03, pool2)

whole cell RNA (14)

• 14297-155B4
• 14300-155B7
• 14303-155C1
• 14306-155C4
• 14309-155C7
• 14312-155D1
• 14315-155D4
• 14318-155D7
• 14321-155E1
• 14324-155E4

... further results

cytoplasmic RNA (8)

• 14304-155C2
• 14307-155C5
• 14313-155D2 (Smooth Muscle Cells - Aortic, donor0 (cytoplasmic fraction))
• 14325-155E5
• 14328-155E8
• 14331-155F2 (Fibroblast - Aortic Adventitial donor2 (cytoplasmic fraction))
• 14334-155F5 (Small Airway Epithelial Cells donor2 (cytoplasmic fraction))
• 14337-155F8

nuclear RNA (14)

• 14299-155B6
• 14302-155B9 (Fibroblast - skin normal, donor2 (nuclear fraction))
• 14305-155C3 (Fibroblast - skin spinal muscular atrophy, donor3 (nuclear fraction))
• 14308-155C6 (Fibroblast - skin dystrophia myotonica, donor3 (nuclear fraction))
• 14311-155C9 (Fibroblast - Aortic Adventitial, donor3 (nuclear fraction))
• 14314-155D3 (Smooth Muscle Cells - Aortic, donor0 (nuclear fraction))
• 14317-155D6 (Small Airway Epithelial Cells, donor3 (nuclear fraction))
• 14320-155D9 (Preadipocyte - breast, donor2 (nuclear fraction))
• 14323-155E3 (Fibroblast - skin normal, donor1 (nuclear fraction))
• 14326-155E6 (Fibroblast - skin spinal muscular atrophy, donor1 (nuclear fraction))

... further results